Cancer Experiences during the COVID-19 Pandemic Version 1
Research type
Research Study
Full title
Experiences of Cancer Diagnostic Pathways and Care during the COVID-19 Pandemic
IRAS ID
297392
Contact name
Una Macleod
Contact email
Sponsor organisation
University of Hull
Duration of Study in the UK
1 years, 2 months, 5 days
Research summary
The global coronavirus (COVID-19) outbreak has led to disruptions in cancer care services, national lockdowns and mandatory self-isolation by people with life-limiting illnesses (including cancer patients). This has resulted in a 76% drop in urgent cancer referrals and a 60% reduction in treatment among patients in the UK (1). The implications these diagnostic and treatment delays have for the physical, mental, emotional and social wellbeing of cancer patients is currently not well understood as the majority of cancer care research conducted during the pandemic have predominantly been quantitative. Therefore, this study will address this research gap by exploring experiences of cancer diagnosis and care during the COVID-19 pandemic from patients’, their informal caregivers’ and healthcare professionals’ perspectives. Insights gleaned from this study will be used to inform policy and practice for improved patients’ experiences and cancer care during immediate and future pandemics.
1 Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, et al. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. medRxiv 2020. (doi.org/10.1101/2020.05.27.20083287)REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
21/NE/0154
Date of REC Opinion
20 Oct 2021
REC opinion
Further Information Favourable Opinion